Ambroxol

RESPIRATORY SYSTEM

Key facts

Ambroxol is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1978. DrugCentral lists 4 molecular targets, including CYP2D6, SLC6A4 and GBA. Recorded indications include Sore throat symptom.

• Molecular targets: CYP2D6, SLC6A4, GBA and SCN10A (4 listed in DrugCentral).
• Indications: Sore throat symptom.
• ATC code: R02AD05 (Anesthetics, local).
• Molecular formula: C13H18Br2N2O; molecular weight 378.11 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Sore throat symptom

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Cytochrome P450 2D6	CYP2D6	unknown	IC50 6.25
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 5.74
Glucosylceramidase	GBA	unknown	IC50 5.39
Sodium channel protein type 10 subunit alpha	SCN10A	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
R02AD05	RESPIRATORY SYSTEM › THROAT PREPARATIONS › THROAT PREPARATIONS › Anesthetics, local
R03CC63	RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Selective beta-2-adrenoreceptor agonists
R05CB06	RESPIRATORY SYSTEM › COUGH AND COLD PREPARATIONS › EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS › Mucolytics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Fractional exhaled nitric oxide increased	363.8
Myoglobin blood increased	285.0
Brain natriuretic peptide increased	258.2
Plantar fasciitis	240.8
Sensation of foreign body	230.0
Pneumothorax	197.6
Macular degeneration	171.0
Hepatic function abnormal	162.9
Pneumonia	161.9
Interstitial lung disease	160.1
Female genital tract fistula	144.3
Vaginal flatulence	140.4

Chemical structure

• Molecular formula: C₁₃H₁₈Br₂N₂O
• Molecular weight: 378.11 g/mol
• CAS number: —
• InChIKey: JBDGDEWWOUBZPM-XYPYZODXSA-N
• PubChem CID: 2132

NC1=C(CN[C@H]2CC[C@H](O)CC2)C=C(Br)C=C1Br

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ambroxol used for?

DrugCentral lists the following indications for Ambroxol: Sore throat symptom.

How does Ambroxol work?

Its molecular targets in DrugCentral include CYP2D6, SLC6A4, GBA and SCN10A.

When was Ambroxol first approved?

Ambroxol was first approved by the YEAR INTRODUCED in 1978.

What is the chemical formula of Ambroxol?

Ambroxol has the molecular formula C13H18Br2N2O and a molecular weight of 378.11 g/mol.

Sources

• DrugCentral drug card 147 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL153479 — compound record and bioactivity
• PubChem CID 2132 — chemical identifiers
• DrugBank DB06742 — drug record
• FDA UNII 200168S0CL — substance identity
• UniProt P10635 (CYP2D6) — target protein
• UniProt P31645 (SLC6A4) — target protein
• UniProt P04062 (GBA) — target protein
• UniProt Q9Y5Y9 (SCN10A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.